Efficacy and Safety of Endoscopic Treatment for Chronic Hemorrhagic Radiation Enteropathy: A Systematic Review and Meta-analysis.

Adv TherJul 21, 2026 (epub)
Clinical ResearchGastroenterologyOncology (Medical)Open access

Yue Sun, Yuhang Yin, Siqi Jia et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy and safety of endoscopic treatments for chronic hemorrhagic radiation enteropathy in 2626 patients. The study found that argon plasma coagulation (APC) achieved a clinical success rate of 95% and a mean hemoglobin increase of 20.61 g/L, indicating high effectiveness and safety of endoscopic interventions.

Key findings

  • Argon plasma coagulation (APC) had a clinical success rate of 95% and a mean hemoglobin increase of 20.61 g/L.
  • Radiofrequency ablation achieved a clinical success rate of 100% with a mean hemoglobin increase of 20.33 g/L.
  • After laser treatment, the clinical success rate was 87%, and for cryotherapy, it was 92%.

Why it matters

Chronic hemorrhagic radiation enteropathy is a significant complication of pelvic radiotherapy, and effective management is crucial. This review highlights the potential of endoscopic treatments to improve patient outcomes and reduce the need for more invasive procedures.

Source

PubMed · PMID 42479097Free full text on PubMed Central

Published in Adv Ther. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.